AstraZeneca PLC (AZN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AstraZeneca PLC (AZN) has a cash flow conversion efficiency ratio of 0.057x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX2.91 Billion ≈ $353.53K USD) by net assets (GBX50.63 Billion ≈ $6.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AstraZeneca PLC (AZN) market capitalisation for the company's overall valuation and market capitalisation.
AstraZeneca PLC - Cash Flow Conversion Efficiency Trend (1990–2025)
This chart illustrates how AstraZeneca PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AstraZeneca PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AstraZeneca PLC ranked by their cash flow conversion efficiency. Explore AZN operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NBCC (India) Limited
NSE:NBCC
|
-0.384x |
|
Sichuan Development Lomon Co Ltd
SHE:002312
|
0.017x |
|
Coface SA
PA:COFA
|
0.021x |
|
SCHOTT Pharma AG & Co. KGaA
XETRA:1SXP
|
0.096x |
|
Huaming Power Equipment Co Ltd
SHE:002270
|
0.013x |
|
Guangdong Feinan Resources Recycling Co Ltd
SHE:301500
|
N/A |
|
DO & CO Aktiengesellschaft
VI:DOC
|
0.150x |
|
NBT Bancorp Inc
NASDAQ:NBTB
|
0.042x |
Annual Cash Flow Conversion Efficiency for AstraZeneca PLC (1990–2025)
The table below shows the annual cash flow conversion efficiency of AstraZeneca PLC from 1990 to 2025. View current stock price of AstraZeneca PLC for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX48.72 Billion ≈ $5.93 Million |
GBX14.57 Billion ≈ $1.77 Million |
0.299x | +3.09% |
| 2024-12-31 | GBX40.87 Billion ≈ $4.97 Million |
GBX11.86 Billion ≈ $1.44 Million |
0.290x | +9.87% |
| 2023-12-31 | GBX39.17 Billion ≈ $4.77 Million |
GBX10.35 Billion ≈ $1.26 Million |
0.264x | -0.20% |
| 2022-12-31 | GBX37.06 Billion ≈ $4.51 Million |
GBX9.81 Billion ≈ $1.19 Million |
0.265x | +74.37% |
| 2021-12-31 | GBX39.29 Billion ≈ $4.78 Million |
GBX5.96 Billion ≈ $725.52K |
0.152x | -50.54% |
| 2020-12-31 | GBX15.64 Billion ≈ $1.90 Million |
GBX4.80 Billion ≈ $583.90K |
0.307x | +50.87% |
| 2019-12-31 | GBX14.60 Billion ≈ $1.78 Million |
GBX2.97 Billion ≈ $361.24K |
0.203x | +9.12% |
| 2018-12-31 | GBX14.04 Billion ≈ $1.71 Million |
GBX2.62 Billion ≈ $318.53K |
0.186x | -13.30% |
| 2017-12-31 | GBX16.64 Billion ≈ $2.02 Million |
GBX3.58 Billion ≈ $435.34K |
0.215x | -13.54% |
| 2016-12-31 | GBX16.67 Billion ≈ $2.03 Million |
GBX4.14 Billion ≈ $504.33K |
0.249x | +37.96% |
| 2015-12-31 | GBX18.44 Billion ≈ $2.24 Million |
GBX3.32 Billion ≈ $404.43K |
0.180x | -49.83% |
| 2014-12-31 | GBX19.65 Billion ≈ $2.39 Million |
GBX7.06 Billion ≈ $858.75K |
0.359x | +12.89% |
| 2013-12-31 | GBX23.25 Billion ≈ $2.83 Million |
GBX7.40 Billion ≈ $900.37K |
0.318x | +9.71% |
| 2012-12-31 | GBX23.95 Billion ≈ $2.91 Million |
GBX6.95 Billion ≈ $845.37K |
0.290x | -12.94% |
| 2011-12-31 | GBX23.47 Billion ≈ $2.86 Million |
GBX7.82 Billion ≈ $951.59K |
0.333x | -26.96% |
| 2010-12-31 | GBX23.41 Billion ≈ $2.85 Million |
GBX10.68 Billion ≈ $1.30 Million |
0.456x | -19.08% |
| 2009-12-31 | GBX20.82 Billion ≈ $2.53 Million |
GBX11.74 Billion ≈ $1.43 Million |
0.564x | +3.58% |
| 2008-12-31 | GBX16.06 Billion ≈ $1.95 Million |
GBX8.74 Billion ≈ $1.06 Million |
0.544x | +8.11% |
| 2007-12-31 | GBX14.91 Billion ≈ $1.81 Million |
GBX7.51 Billion ≈ $913.75K |
0.504x | +0.90% |
| 2006-12-31 | GBX15.42 Billion ≈ $1.88 Million |
GBX7.69 Billion ≈ $936.02K |
0.499x | +1.32% |
| 2005-12-31 | GBX13.69 Billion ≈ $1.67 Million |
GBX6.74 Billion ≈ $820.43K |
0.493x | +46.52% |
| 2004-12-31 | GBX14.50 Billion ≈ $1.76 Million |
GBX4.87 Billion ≈ $592.90K |
0.336x | +30.45% |
| 2003-12-31 | GBX13.26 Billion ≈ $1.61 Million |
GBX3.42 Billion ≈ $415.63K |
0.258x | -40.17% |
| 2002-12-31 | GBX11.22 Billion ≈ $1.37 Million |
GBX4.83 Billion ≈ $588.04K |
0.431x | +53.24% |
| 2001-12-31 | GBX9.63 Billion ≈ $1.17 Million |
GBX2.71 Billion ≈ $329.30K |
0.281x | +14.89% |
| 2000-12-31 | GBX9.55 Billion ≈ $1.16 Million |
GBX2.34 Billion ≈ $284.22K |
0.245x | +178.60% |
| 1999-12-31 | GBX10.35 Billion ≈ $1.26 Million |
GBX908.55 Million ≈ $110.54K |
0.088x | +9.62% |
| 1998-12-31 | GBX10.98 Billion ≈ $1.34 Million |
GBX879.74 Million ≈ $107.04K |
0.080x | -61.15% |
| 1997-12-31 | GBX3.62 Billion ≈ $440.89K |
GBX747.21 Million ≈ $90.91K |
0.206x | -4.16% |
| 1996-12-31 | GBX3.66 Billion ≈ $445.48K |
GBX787.75 Million ≈ $95.85K |
0.215x | +11.55% |
| 1995-12-31 | GBX3.04 Billion ≈ $369.44K |
GBX585.64 Million ≈ $71.25K |
0.193x | -15.95% |
| 1994-12-31 | GBX2.73 Billion ≈ $331.56K |
GBX625.36 Million ≈ $76.09K |
0.229x | -24.42% |
| 1993-12-31 | GBX2.32 Billion ≈ $282.74K |
GBX705.58 Million ≈ $85.85K |
0.304x | -75.00% |
| 1992-12-31 | GBX169.87 Million ≈ $20.67K |
GBX206.27 Million ≈ $25.10K |
1.214x | +120.37% |
| 1991-12-31 | GBX916.88 Million ≈ $111.56K |
GBX505.22 Million ≈ $61.47K |
0.551x | -53.33% |
| 1990-12-31 | GBX682.84 Million ≈ $83.08K |
GBX806.30 Million ≈ $98.10K |
1.181x | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splend… Read more